Novo Nordisk A/S announced it will invest €432 million (approximately DKK 3.2 billion) to expand its manufacturing facility in Monksland, Athlone, Ireland, increasing production capacity for oral GLP-1 treatments serving markets outside the US.
The Denmark-headquartered pharmaceutical company said the investment will upgrade and retrofit its existing tabletting facility, enhancing its ability to manufacture oral products, strengthen supply, and position Ireland as a key hub for servicing international markets. The expansion supports current and future GLP-1 treatments and marks what the company described as a major strategic milestone.
The Athlone plant, which spans 45 acres, currently employs 260 people. Those employees will continue focusing on delivering oral treatments in an efficient and environmentally sustainable manner. The project is also expected to create up to 500 construction jobs, with work already underway and completion scheduled gradually from late 2027 through 2028.
Founded in 1923 and headquartered in Denmark, Novo Nordisk employs approximately 68,800 people across 80 countries and markets its products in around 170 countries.
KEY QUOTE:
“With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will strengthen our ability to meet both current and future demand, outside the US,” added Kasper Bødker Mejlvang, EVP CMC & Product Supply, Novo Nordisk. “This investment, a historic milestone for Novo Nordisk in Ireland, marks our continued commitment to Ireland and our highly skilled employees in Athlone while allowing us to make a difference for millions of people living with serious chronic diseases.”
Kasper Bødker Mejlvang, EVP CMC & Product Supply, Novo Nordisk
